BioAv Cancer Research Results
BioAv, bioavailability: Click to Expand ⟱
| Source: |
| Type: measurement |
Bioavailability (usually in %) absorbed by the body.
|
CRC, Colorectal Cancer: Click to Expand ⟱
Colorectal cancer is a broader term that encompasses both colon and rectal cancer.
|
Scientific Papers found: Click to Expand⟱
*Inflam↓, *antiOx↑, *cardioP↑, *neuroP↑, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, CDC2↓, AMPK↝, mTOR↝, Casp8↑, Casp9↑, Cyt‑c↑, TumCMig↓, TumCI↓, EMT↓, MMPs↓, E-cadherin↓, Telomerase↓, *toxicity↓, GRP78/BiP↓, EGFR↓, CDK4↓, COX2/PTGS2↓, PGE2↓, p‑JAK2↓, p‑STAT3↓, MMP2↓, MMP9↓, GutMicro↑, eff↝, *BioAv↓, BioAv↑,
eff↑, BioAv↑, eff↑,
DDS↑, eff↑, BioAv↑, BioEnh↑, eff↑,
*Inflam↓, *antiOx↑, AntiCan↑, BioAv↑, Apoptosis↑, angioG↓, Imm↝, ChemoSen↑, chemoP↑,
AntiCan↑, p‑Akt↓, TF-Ag↓, *PI3K↓, *AP-1↓, *DNArepair↑, *BioAv↑, *BBB↑, *other↑, *PGE2↓,
*toxicity↓, Risk↓, MMPs↓, VEGF↓, VEGFR1↓, Wnt↓, β-catenin/ZEB1↑, PI3K↓, Akt↓, mTOR↓, ChemoSen↑, *BioAv↓, TumCCA↑, Apoptosis↑, Hif1a↓, ROS↑, TumCMig↓, TumMeta↓, PKM2↓, Glycolysis↓, DNAdam↑, HO-1↑, Ferroptosis↑, eff↑, Dose↝, BioAv↑,
| - |
in-vitro, |
RCC, |
RCC4 |
|
|
|
- |
in-vitro, |
CRC, |
HCT116 |
|
|
|
- |
in-vitro, |
BC, |
MDA-MB-435 |
|
|
|
- |
in-vitro, |
Ovarian, |
SKOV3 |
|
|
|
- |
in-vitro, |
Colon, |
SW48 |
|
|
|
- |
in-vitro, |
GBM, |
U251 |
|
|
|
eff↑, Warburg↓, BioAv↑, ROS↑, DNAdam↑, ATP↓, eff↑, necrosis↑, PARP↑,
Showing Research Papers: 1 to 7 of 7
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 7
Pathway results for Effect on Cancer / Diseased Cells:
NA, unassigned(tgid=0) ⓘ
TF-Ag↓, 1,
Redox & Oxidative Stress(tgid=1) ⓘ
Ferroptosis↑, 1, HO-1↑, 1, ROS↑, 2,
Mitochondria & Bioenergetics(tgid=3) ⓘ
ATP↓, 1, CDC2↓, 1,
Core Metabolism/Glycolysis(tgid=4) ⓘ
AMPK↝, 1, Glycolysis↓, 1, PKM2↓, 1, Warburg↓, 1,
Cell Death(tgid=5) ⓘ
Akt↓, 1, p‑Akt↓, 1, Apoptosis↑, 2, Casp8↑, 1, Casp9↑, 1, Cyt‑c↑, 1, Ferroptosis↑, 1, necrosis↑, 1, Telomerase↓, 1,
Protein Folding & ER Stress(tgid=8) ⓘ
GRP78/BiP↓, 1,
DNA Damage & Repair(tgid=10) ⓘ
DNAdam↑, 2, PARP↑, 1,
Cell Cycle & Senescence(tgid=11) ⓘ
CDK4↓, 1, cycD1/CCND1↓, 1, cycE/CCNE↓, 1, TumCCA↑, 2,
Proliferation, Differentiation & Cell State(tgid=12) ⓘ
EMT↓, 1, mTOR↓, 1, mTOR↝, 1, PI3K↓, 1, p‑STAT3↓, 1, Wnt↓, 1,
Migration(tgid=13) ⓘ
E-cadherin↓, 1, MMP2↓, 1, MMP9↓, 1, MMPs↓, 2, TumCI↓, 1, TumCMig↓, 2, TumMeta↓, 1, VEGFR1↓, 1, β-catenin/ZEB1↑, 1,
Angiogenesis & Vasculature(tgid=14) ⓘ
angioG↓, 1, EGFR↓, 1, Hif1a↓, 1, VEGF↓, 1,
Immune & Inflammatory Signaling(tgid=16) ⓘ
COX2/PTGS2↓, 1, Imm↝, 1, p‑JAK2↓, 1, PGE2↓, 1,
Drug Metabolism & Resistance(tgid=21) ⓘ
BioAv↑, 6, BioEnh↑, 1, ChemoSen↑, 2, DDS↑, 1, Dose↝, 1, eff↑, 7, eff↝, 1,
Clinical Biomarkers(tgid=22) ⓘ
EGFR↓, 1, GutMicro↑, 1,
Functional Outcomes(tgid=23) ⓘ
AntiCan↑, 2, chemoP↑, 1, Risk↓, 1,
Total Targets: 61
Pathway results for Effect on Normal Cells:
Redox & Oxidative Stress(tgid=1) ⓘ
antiOx↑, 2,
Transcription & Epigenetics(tgid=7) ⓘ
other↑, 1,
DNA Damage & Repair(tgid=10) ⓘ
DNArepair↑, 1,
Proliferation, Differentiation & Cell State(tgid=12) ⓘ
PI3K↓, 1,
Migration(tgid=13) ⓘ
AP-1↓, 1,
Barriers & Transport(tgid=15) ⓘ
BBB↑, 1,
Immune & Inflammatory Signaling(tgid=16) ⓘ
Inflam↓, 2, PGE2↓, 1,
Drug Metabolism & Resistance(tgid=21) ⓘ
BioAv↓, 2, BioAv↑, 1,
Functional Outcomes(tgid=23) ⓘ
cardioP↑, 1, neuroP↑, 1, toxicity↓, 2,
Total Targets: 13
Scientific Paper Hit Count for: BioAv, bioavailability
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:6 Cells:% prod#:% Target#:792 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid
Home Page